Impact de la polémique sur la possible "relation vaccin contre l'hépatite B et la sclérose en plaques" sur la prescription et la pratique de cette vaccination par les médecins généralistes du Vaucluse

AIX-MARSEILLE2-BU Méd/Odontol. (130552103) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Sofosbuvir plus velpatasvir plus voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, AUSTRIA, APR 10-14, 2019International audienc

Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, NOV 09-13, 2018International audienc

Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, NOV 09-13, 2018International audienc

Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, NOV 09-13, 2018International audienc

Sofosbuvir plus Velpatasvir plus Voxilaprevir in Daa Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA, NOV 09-13, 2018International audienc

Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals

Introduction and aim: Data on the efficacy and tolerance of interferon-free treatment in chronic hepatitis C (CHC) in elderly patients are limited in phase II-III trials. Material and methods: A prospective cohort of adult patients with CHC treated in French general hospitals. Results: Data from 1,123 patients, distributed into four age groups, were analyzed. Of these, 278 were > 64 years old (fourth quartile) and 133 were > 73 years old (tenth decile). Elderly patients weighed less, were more frequently treatment-experienced women infected with genotype 1b or 2, while they less frequently had genotype 3 or HIV coinfection, but had more frequent comorbidities and drug consumption. Half of the patients had cirrhosis, whatever their ages. The main treatment regimens were sofosbuvir/ledipasvir (37.8%), sofosbuvir/daclatasvir (31.8%), sofosbuvir/simeprevir (16.9%), sofosbuvir/ribavirin (7.8%); ribavirin was given to 24% of patients. The overall sustained virological response (SVR) rate was 91.0 % (95% CI: 89.292.5%) with no difference according to age. Logistic regression of the independent predictors of SVR were albumin, hepatocellular carcinoma and treatment regimen, but not age. The rate of severe adverse events (66 in 59/1062 [5.6%] patients) tended to be greater in patients older than 64 years of age (21/261,8.1%), but the only independent predictors of SAE by logistic regression were cirrhosis and baseline hemoglobin. Patient-reported overall tolerance was excellent in all age groups, and patient-reported fatigue decreased during and after treatment, independent of age. Conclusions: The high efficacy and tolerance of interferon-free regimens is confirmed in elderly patients in real-life conditions